Foghorn Therapeutics Inc.
Foghorn Therapeutics discovers and develops medicines targeting chromatin regulatory system dependencies using its Gene Traffic Control platform.
10-QNov 9Latest SEC filing
Nov 9Latest story
November 2026
October 2026
August 2026